Item 7.01. Regulation FD Disclosure.



As previously announced, TYME will be presenting its poster "Oral SM-88 plus
MPS: an effective yet less toxic treatment option in second-line advanced
pancreatic cancer? Final Phase II/III study results" at the 2022 American
Society of Clinical Oncology ("ASCO") Gastrointestinal Cancer Symposium, which
is being held both online and in person in San Francisco, CA from January 20-22,
2022. TYME's presentation is scheduled to take place at 3:05 p.m. Eastern
Standard Time on January 21, 2022.

In the poster, TYME presents the final results of Part 1 of its multicenter,
prospective open-label trial, TYME-88-Panc, studying SM-88 in late-stage
patients with advanced pancreatic cancer. As previously disclosed, TYME has
discontinued the TYME-88-Panc trial and, accordingly, will not be presenting any
further results, including results of Part 2 of the Study.

Additional information on the meeting can be found on the ASCO 2022
Gastrointestinal Cancers Symposium website at
https://conferences.asco.org/gi/program. Information on ASCO's website is not
incorporated by reference herein. A copy of the poster is available on our
website at
https://tymeinc.com/data-publications/scientific-presentations/default.aspx?_ga=2.14989942.1910725466.1642085084-49066985.1641324922.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses